From: The impact of the COVID-19 Pandemic on rhegmatogenous retinal detachment treatment patterns
 | PPV (162) | SB (96) | P |
---|---|---|---|
group (COVID/pre-COVID) | 57/105 | 22/74 | 0.054 |
gender (male/female) | 100/62 | 60/36 | 1 |
age (mean±SD, y) | 52.7 + 13.6 | 39.9 + 19.9 | < 0.001 |
presurgery waiting time (median, d) | 4 [2,8] | 4 [3,12] | 0.51 |
RRD-CD (n) | 55 | 17 | < 0.001 |
dense VH (n) | 7 | 3 | 0.74 |
recurrent RRD (n) | 19 | 4 | 0.04 |
VA less than 0.02 (n) | 99 | 24 | < 0.001 |
VA 0.02-0.1 (n) | 45 | 31 | 0.48 |
VA 0.1-0.5 (n) | 13 | 30 | < 0.001 |
VA greater than 0.5 (n) | 5 | 11 | 0.01 |
PM (n) | 57 | 23 | 0.08 |
pseudophakia (n) | 35 | 7 | 0.004 |
retinal breaks location (n) | Â | Â | Â |
anterior | 69 | 82 | < 0.001 |
posterior | 67 | 12 | < 0.001 |
macular hole (n) | 2 | 26 | 0.0003 |
macular-off (n) | 15 | 33 | < 0.001 |
PVR B-C (n) | 128 | 96 | < 0.001 |